To provide the information your oncologist is not telling you or doesn't have the time to!
Multiple myeloma, a complex and challenging hematologic malignancy, has seen remarkable advances in its treatment landscape. Standard care for transplant-eligible patients often involves quad therapy, blending immunomodulatory agents, proteasome inhibitors, anti-CD38 monoclonal antibodies, and corticosteroids. For frail or comorbid patients, triple therapy remains the mainstay. Hospitalized patients frequently benefit from CyBORD (cyclophosphamide, bortezomib, dexamethasone), and …
Cancer cachexia is a debilitating condition that affects a significant portion of cancer patients, characterized by involuntary weight loss, muscle wasting, and metabolic dysfunction. Beyond its physical toll, cachexia diminishes quality of life and complicates cancer treatment, making it a critical issue in oncology. Despite its prevalence, effective treatments have been limited—until now. Recent advancements, …
Stage IV melanoma used to be synonymous with a terminal diagnosis. For years, oncologists faced the grim reality of limited options and poor survival rates for their patients. However, the landscape has changed dramatically over the past decade. Breakthroughs in immunotherapy and clinical research have rewritten the narrative, offering hope to patients and their families. …
As the holiday season wraps up and 2024 comes to a close, I find myself reflecting on a year that has been both transformative and rejuvenating. This year has been different from any I’ve experienced before—a year of intentional living, personal growth, and deep gratitude. For the past 13 years, I was rooted in a …
Medical malpractice in oncology is a topic that often stirs emotions on all sides—patients, families, and physicians. For patients and caregivers, it may represent a loss of trust and unmet expectations. For providers, it can be a deeply personal challenge that touches the very heart of their commitment to care. In oncology, where time, precision, …
The management of chronic lymphocytic leukemia (CLL), one of the most common types of leukemia, has advanced significantly over the past decade. New targeted therapies have reshaped treatment paradigms, providing effective, less toxic options compared to traditional chemoimmunotherapy. At the 2024 ASH Annual Meeting, data from the phase 3 AMPLIFY trial introduced another potential breakthrough …
When facing a cancer diagnosis, timing can profoundly impact outcomes, both physically and emotionally. For some malignancies, delays in diagnosis or treatment can lead to disease progression, impacting prognosis and available treatment options. However, the urgency to act must also be balanced with the need for accurate diagnosis and a well-considered treatment plan. This article …
Cutaneous squamous cell carcinoma (CSCC) is one of the most common skin cancers, with cases ranging from easily treatable localized lesions to aggressive forms that can metastasize or become life-threatening. On December 13, 2024, the FDA approved cosibelimab-ipdl (Unloxcyt), a PD-L1 blocking antibody, offering new hope for adults with metastatic CSCC (mCSCC) or locally advanced …
The recent story of unethical practices by a medical oncologist raises significant concerns and offers an opportunity to discuss red flags that patients, families, and even healthcare providers should be aware of when navigating cancer care. While most oncologists are guided by ethical principles and bound by professional accountability, recognizing warning signs can empower patients …
As an oncology research nurse, I have the unique privilege of being part of a team that brings the latest innovations in cancer treatment to life through clinical trials. My role extends far beyond the walls of the research lab or the clinic—it’s about making research accessible, meaningful, and impactful for patients who are navigating …